A series of 5-phenyl-3-ureidobenzodiazepine-2,4-diones was synthesized and evaluated as cholecystokinin-B (CCK-B) receptor antagonists. Structure-activity relationship (SAR) studies revealed the importance of the N-1 substituent for potent and selective CCK-B affinity. Addition of substituents at the urea side chain provided in some cases more potent compounds. Moreover the introduction of bulky substituents
合成了一系列5-苯基-3-
脲基苯并二氮杂-2,4-二酮,并作为胆囊收缩素-B(CCK-B)受体拮抗剂进行了评估。结构活性关系(
SAR)研究表明,N-1取代基对于有效和选择性CCK-B亲和力的重要性。在某些情况下,在
脲侧链上添加取代基可提供更有效的化合物。此外,在N-1处引入笨重的取代基(如
金刚烷基甲基)和拆分外消旋
脲导致了我们的
铅化合物GV150013。